作者:Anna Ju、Huiyun Seo、Heemun Kim、Byoung Chul Park、Sung Goo Park、Jeong Hoon Kim、Hyung-Kyoon Choi、Kyung Hoon Min、Sayeon Cho
DOI:10.1246/bcsj.20130221
日期:2014.3.15
The Src homology 2 (SH2) domain-containing phosphatase 2 (SHP-2) is a nonreceptor protein tyrosine phosphatase (PTP) involved in extracellular-regulated kinase (ERK) activation. Recent studies have shown that gain-of-function mutations in SHP-2 are associated with several diseases, including LEOPARD syndrome, Noonan syndrome, and juvenile myelomonocytic leukemia. In this study, we identified the novel SHP-2 inhibitor 3-(1-benzimidazolylmethyl)-6-p-tolyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole (MLS-001). SHP-2 activity was inhibited by MLS-001, whereas other types of PTPs, namely ACP1, CDC25A, DUSP3, DUSP14, DUSP18, DUSP22, DUSP23, DUSP26, and SSH3, were not. Furthermore, TCPTP and SHP-1 that are closely related to SHP-2 were not inhibited by the inhibitor. Kinetic studies with MLS-001 and SHP-2 revealed a competitive inhibition. The SHP-2 expressing cells treated with MLS-001 demonstrated reduced SHP-2 phosphatase activity, thereby suggesting that MLS-001 effectively passes through cell membranes. In addition, MLS-001 reduced SHP-2-mediated phosphorylation in the activation loop of ERK in cells. Therefore, MLS-001 could be a lead compound for developing a potent SHP-2 inhibitor.
含有Src同源2(SH2)结构域的磷酸酶2(SHP-2)是一种非受体蛋白酪氨酸磷酸酶(PTP),参与细胞外调节激酶(ERK)的激活。最近的研究表明,SHP-2的功能获得性突变与几种疾病相关,包括LEOPARD综合症、Noonan综合症和青少年髓单核细胞白血病。在本研究中,我们鉴定了一种新的SHP-2抑制剂3-(1-苯并咪唑基甲基)-6-p-甲基苯基-[1,2,4]三唑并[3,4-b][1,3,4]噻二唑(MLS-001)。MLS-001抑制了SHP-2的活性,而其他类型的PTP,例如ACP1、CDC25A、DUSP3、DUSP14、DUSP18、DUSP22、DUSP23、DUSP26和SSH3则未受到抑制。此外,与SHP-2密切相关的TCPTP和SHP-1也未受到该抑制剂的抑制。对MLS-001和SHP-2的动力学研究显示出竞争性抑制。处理过MLS-001的SHP-2表达细胞显示出SHP-2的磷酸酶活性降低,这暗示MLS-001能够有效地穿过细胞膜。此外,MLS-001还降低了细胞中由SHP-2介导的ERK激活环的磷酸化。因此,MLS-001可能成为开发强效SHP-2抑制剂的领先化合物。